Fahy, Caloric Restriction, and the Mimetic Benchmark
Gregory Fahy's work connects to caloric restriction through the hepatic gene-expression profile that long-term CR produces, used as a molecular benchmark for identifying CR mimetics.
Gregory Fahy, Chief Scientific Officer at Intervene Immune, led TRIIM, a clinical trial of thymus regeneration, immunorestoration, and biological-age measures. His connection to caloric restriction runs through a specific mechanism: long-term CR generates a hepatic gene-expression profile, and researchers use that profile as a molecular benchmark for identifying CR mimetics, compounds that replicate CR's metabolic effects without the diet itself.
The CR data: in 58 middle-aged and older adults with obesity and prediabetes, 18 weeks of restriction produced mean weight loss of 10.8 kg and altered composite SASP factors (secretory proteins from senescent cells). In middle-aged nonhuman primates, 10% CR improved body composition and immune-cell profiles, which ties directly to TRIIM's immunorestoration work.
Jamie Justice, Daniel Belsky, Steven Austad, and Luigi Ferrucci work in the same area, each with a different question about CR.
This edge connects a clinician known for thymus regeneration (TRIIM) to a foundational intervention class through a non-obvious molecular angle: CR mimetic identification via hepatic gene expression, rather than CR as diet therapy. The immune-profile data from nonhuman primates also bridges directly to Fahy's core research subject.